Insulet Elevates Eric Benjamin to Chief Operating Officer and Appoints Manoj Raghunandanan as Chief Growth Officer, Strengthening Leadership to Drive Next Phase of Global Expansion
Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology and developer of the Omnipod® brand of products, announced a significant leadership evolution designed to accelerate its growth strategy and deepen its impact on diabetes care. The company has promoted Eric Benjamin to the role of Chief Operating Officer (COO), effective immediately, while also appointing Manoj Raghunandanan as Chief Growth Officer (CGO). These moves reinforce Insulet’s commitment to driving innovation, expanding into new markets, and elevating patient experience at a pivotal time for both the company and the global diabetes community.
A Strategic Leadership Realignment
The leadership changes mark a deliberate reorganization of Insulet’s growth and innovation functions. As COO, Eric Benjamin will now oversee a broad mandate, leading strategy and business development, the office of the Chief Technology Officer, research and development, and the newly created Growth organization. By consolidating these functions under a single leadership structure, Insulet is positioning itself to deliver stronger execution and accelerate its long-term vision of transforming insulin delivery for millions of people worldwide.
At the same time, the appointment of Manoj Raghunandanan as Chief Growth Officer reflects Insulet’s increasing emphasis on scaling globally and driving demand generation in a rapidly expanding market. His mandate includes overseeing global strategy development, commercial acceleration, brand stewardship, and advancing the customer experience—an area that has been central to Insulet’s differentiation in diabetes care.
Together, these appointments reflect Insulet’s recognition that the challenges and opportunities of the diabetes market require bold leadership capable of steering both innovation pipelines and commercial execution simultaneously.
Eric Benjamin: A Proven Leader in Innovation and Execution
Eric Benjamin’s journey at Insulet began in 2015, and over the last decade, he has become one of the company’s most influential leaders. His career at Insulet has been marked by a consistent ability to balance innovation with operational execution—a skillset critical to a company operating at the intersection of healthcare technology and consumer experience.
Benjamin’s contributions have been pivotal across several dimensions:
- Product Innovation: He played a key role in the successful launch of Omnipod DASH® and Omnipod 5®, two breakthrough technologies that advanced the company’s product portfolio. Omnipod 5, notably, became the world’s first tubeless, wearable, automated insulin delivery system integrated with continuous glucose monitoring (CGM).
- Market Expansion: Benjamin spearheaded Insulet’s entry into the type 2 diabetes market, a major milestone that broadened the company’s reach and positioned it to serve a significantly larger patient population.
- Supply Chain Resilience: During periods of global disruption—including the COVID-19 pandemic—Benjamin implemented strategies that strengthened supply chain resilience, ensuring uninterrupted product availability for patients who rely on Insulet’s devices.
- Customer-Centric Digital Transformation: He directed initiatives to digitize Insulet’s customer experience, enhancing engagement, access, and satisfaction. This shift to a more consumer-centric model aligns with broader healthcare trends emphasizing patient empowerment and connectivity.
Most recently, as Executive Vice President, Chief Product & Customer Experience Officer, Benjamin was responsible for global product strategy, customer experience, commercial execution, and shaping Insulet’s long-term innovation roadmap. His promotion to COO is both a recognition of his track record and a signal of the company’s confidence in his ability to lead at a larger scale.
CEO Endorsement and Vision
Ashley McEvoy, President and CEO of Insulet, emphasized the importance of Benjamin’s leadership to the company’s trajectory.
“Eric has been a driving force in Insulet’s success,” McEvoy said. “He combines vision, execution, and a mission-first mindset that sets him apart—spotting opportunities in evolving markets, setting bold strategies, and building high-performing teams that deliver results. I look forward to partnering even more closely with him as we accelerate Insulet’s next chapter of growth and impact. The addition of Manoj’s deep global growth expertise further enhances our leadership and positions us to seize new opportunities ahead.”
McEvoy’s remarks highlight not only Benjamin’s operational skill but also his alignment with Insulet’s mission-driven culture. In a healthcare environment where innovation must translate into real-world patient benefits, leaders like Benjamin are tasked with bridging strategic ambition with operational realities.
Eric Benjamin on His New Role
For Benjamin, the appointment represents both a professional milestone and a personal mission.
“I’m honored to step into this role at such an important moment for Insulet and exciting time in the advancement of diabetes care,” he said. “We have an extraordinary opportunity to continue advancing life-changing technology and broaden global access to improve the lives of people with diabetes.”
His comments reflect the dual focus of Insulet’s strategy: leveraging technology to push the boundaries of what is possible in insulin delivery, while simultaneously scaling access to ensure that innovations reach patients worldwide.
The Appointment of Manoj Raghunandanan: A Global Growth Specialis
Alongside Benjamin’s expanded responsibilities, Insulet announced the appointment of Manoj Raghunandanan as Chief Growth Officer. His arrival marks an infusion of global commercial expertise into Insulet’s executive ranks.
Raghunandanan brings over 20 years of leadership experience in consumer health, most recently at Kenvue (formerly Johnson & Johnson Consumer Health). There, he served as General Manager of the Northern European business and was a member of the Executive Committee for five years, overseeing a $6 billion global OTC portfolio. His track record spans leadership roles in the United States, Europe, and Asia, giving him a uniquely global perspective on scaling healthcare products.
At Insulet, Raghunandanan will oversee the newly-formed Growth organization, with responsibilities including:
- Global Strategy Development: Crafting long-term strategies to drive international expansion.
- Demand Generation: Implementing innovative approaches to expand market penetration and accelerate adoption of Insulet’s technologies.
- Commercial Capabilities: Enhancing sales and marketing execution to maximize growth.
- Brand and Customer Experience: Strengthening Insulet’s global brand positioning and ensuring that customer engagement remains central to the company’s mission.
By appointing a Chief Growth Officer with a proven record in scaling global businesses, Insulet is underscoring its ambition to expand well beyond its current footprint and capitalize on the accelerating demand for diabetes technologies worldwide.
A Transformative Moment for Insulet
The leadership appointments come at a critical time for Insulet and the broader diabetes technology industry. Several factors make this moment particularly significant:
- Rising Global Diabetes Prevalence: The number of people living with diabetes worldwide continues to rise, with the International Diabetes Federation estimating more than 537 million adults affected globally in 2021, a number projected to climb sharply by 2045. This growing patient base increases demand for innovative insulin delivery solutions.
- Shift Toward Automated Insulin Delivery (AID): The market is rapidly moving toward automated solutions that integrate continuous glucose monitoring with insulin pumps. Insulet’s Omnipod 5 is well positioned in this shift, but continued innovation and global expansion are critical to maintaining leadership.
- Healthcare Consumerization: Patients increasingly expect healthcare experiences that mirror consumer technology—seamless, connected, and user-friendly. Insulet’s digital transformation initiatives align with this trend, and the new leadership structure will likely accelerate efforts in this space.
- Competitive Landscape: The insulin delivery market remains highly competitive, with players such as Medtronic, Tandem Diabetes Care, and emerging digital health companies vying for market share. Strategic leadership appointments help Insulet maintain an edge.
- Global Expansion Opportunities: While Insulet has a strong presence in the United States, international markets represent a significant opportunity for growth. Raghunandanan’s expertise in scaling global brands is expected to play a central role in this endeavor.
Strengthening the Innovation-to-Market Pipeline
By combining Eric Benjamin’s oversight of product development, strategy, and operations with Manoj Raghunandanan’s commercial expertise, Insulet is creating a seamless pipeline from innovation to market execution. This structure ensures that breakthrough products not only get developed but also reach patients globally with speed and efficiency.
This end-to-end alignment of teams and priorities could prove decisive in Insulet’s ability to stay ahead in an industry where technology cycles are accelerating, and customer expectations are evolving rapidly.
With these leadership changes, Insulet signals its intent to enter its next chapter of growth with renewed momentum. The company is doubling down on three core priorities:
- Advancing Product Innovation: Continuing to invest in R&D to expand the Omnipod platform and explore new technologies for diabetes management.
- Expanding Global Access: Scaling operations and commercial capabilities to serve a broader patient base, particularly in emerging markets.
- Enhancing Customer Experience: Leveraging digital tools, customer engagement strategies, and brand development to ensure a best-in-class experience for people with diabetes.
These moves come against the backdrop of increasing recognition that medical technology companies must combine innovation with operational excellence and customer-centricity to achieve sustainable impact.
The promotion of Eric Benjamin to Chief Operating Officer and the appointment of Manoj Raghunandanan as Chief Growth Officer represent more than just personnel changes—they signal a strategic realignment at Insulet designed to accelerate growth, strengthen innovation, and deepen global impact.
For Insulet, which has already redefined insulin delivery through its Omnipod systems, the stakes have never been higher. With global diabetes prevalence rising, competitive pressures intensifying, and technology cycles accelerating, the company is positioning itself with the leadership talent needed to sustain its trajectory as an innovation-driven, patient-focused healthcare leader.
As Insulet embarks on this new chapter, the company appears poised not only to extend its leadership in tubeless insulin pump technology but also to play a transformative role in shaping the future of diabetes care worldwide.
